Target intelligence / Profile preview

Uric acid transporter protein

Molecular classification
Transporter, Solute carrier family protein, ATP-binding cassette transporter (for MRP4/ABCC4, ABCG2), Organic anion transporter, Glucose transporter (for GLUT9/SLC2A9)
01

Overview

Uric acid transporter proteins in kidney tubules are a family of membrane transporters expressed predominantly in the renal proximal tubule, and are crucial for the regulation of uric acid (urate) homeostasis in humans. This group includes reabsorptive transporters such as urate anion transporter 1 (URAT1/SLC22A12), glucose transporter 9 (GLUT9/SLC2A9), and organic anion transporter 4 (OAT4/SLC22A11), as well as secretory transporters such as organic anion transporter 1 (OAT1/SLC22A6), OAT3 (SLC22A8), multidrug resistance-associated protein 4 (MRP4/ABCC4), ABCG2, and sodium-dependent phosphate cotransporters (NPT1/SLC17A1, NPT4/SLC17A3). Together, these proteins mediate the balance between urate reabsorption and excretion, determining plasma uric acid concentrations. Dysregulation or genetic variation in these transporters is linked with gout, kidney stones, and other urate-related disorders, and thus specific transporters, especially URAT1 and GLUT9, are considered major therapeutic targets for uricosuric drugs.

Other names
urate transportersrenal uric acid transportersuric acid transport proteinsrenal proximal tubule urate transporters
02

Mechanism of action

Inhibition of urate reabsorption by blocking URAT1 or GLUT9; Increased urate excretion by inhibiting reabsorptive transporters or enhancing efflux (via ABCG2, MRP4); Modulation of overall uric acid balance through transporter inhibition

03

Biological functions

Uric acid reabsorptionUric acid excretionMaintenance of uric acid homeostasisRegulation of serum urate levels
04

Disease associations

GoutHyperuricemiaKidney stone formationDiabetes (via uric acid metabolism influence)Renal dysfunction
05

Safety considerations

Risk of nephrolithiasis (kidney stones) from increased urate excretionRisk of renal impairment or injury with excessive uricosuric therapyDrug-drug interactions affecting transporter activityHypersensitivity and off-target effects with some inhibitors
06

Interacting drugs

Lesinurad (URAT1 inhibitor)

5 more in the full profile.

07

Biomarkers

Serum uric acid levelGenetic variants (SNPs) in urate transporter genes (e.g., SLC2A9, SLC22A12)Urinary urate excretion rate

Beyond the preview

Go deeper on Uric acid transporter protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uric acid transporter protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call